Vivoryon Therapeutics N.v.

Vivoryon Therapeutics N.V. is a clinical-stage biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly Alzheimer's disease. The company is known for its proprietary technology platform that targets the modulation of protein misfolding and aggregation, aiming to restore normal cellular function. Vivoryon's lead product candidate, PQ912, is designed to inhibit the activity of the enzyme that contributes to the formation of toxic protein aggregates. The company is committed to advancing its pipeline through clinical trials and collaborations, with the goal of providing effective treatments for patients suffering from debilitating neurological conditions.